TriangleDabrafenib (NCT07110246)
Dabrafenib trial for BRAF V600 Mutation (NCT07110246). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged one to under 25 with BRAF V600-mutant low-grade glioma, newly diagnosed or recurrent/progressive. Molecular documentation and cohort-specific prior-treatment rules apply.
The idea: dabrafenib and trametinib block growth signals. After 12–24 treatment cycles, patients are randomized to stop both drugs or taper over six more cycles. Researchers compare tumor rebound. Both drugs are oral; spinal-fluid collection is optional.
This phase 2 study plans 96 patients. Sabine Mueller leads at the University of California, San Francisco, with 12 recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.